跳至主要内容
临床试验/EUCTR2007-004139-49-IT
EUCTR2007-004139-49-IT进行中(未招募)1 期

Efficacy and tolerability of 12-weeks oral treatment with V0355CP3A versus Ferrograd, in iron deficiency anaemia. Multicenter, randomised, open-label trial. - ND

PIERRE FABRE MEDICAMENT0 个研究点目标入组 300 人开始时间: 2007年12月10日最近更新:
相关药物

试验速览

阶段
1 期
状态
进行中(未招募)
入组人数
300

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

入选标准

  • Ambulatory female between 18 and 50 years. Haemoglobin level between 90 g/L and 120 g/L. Serum ferritin level < 30 µg/L). Willing to participate. Able to understand the protocol, to comply with its requirements and to attend to visits. Have given their written informed consent to participate in the study;
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range
  • F.1.3 Elderly (>=65 years) no
  • F.1.3.1 Number of subjects for this age range

排除标准

  • For women with childbearing potential:
  • o not using effective contraception (oral contraceptives, intrauterine device, tubal
  • ligation or other efficient procedures ),
  • o pregnant, breast feeding or likely to become pregnant during the time of the study
  • o positive urinary pregnancy test.
  • Anaemia related to other causes than iron deficiency.
  • Inflammatory bowel disease or any digestive disease.

研究者

相似试验